ed8896f8-24ef-43a4-ace6-ed9353bd11c2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.160
- UV_RESPONSE_DN+0.130
- MITOTIC_SPINDLE+0.100
- PROTEIN_SECRETION+0.070
- ANDROGEN_RESPONSE+0.040
- BILE_ACID_METABOLISM-0.010
- TGF_BETA_SIGNALING-0.030
- KRAS_SIGNALING_DN-0.050
- HEDGEHOG_SIGNALING-0.100
- PI3K_AKT_MTOR_SIGNALING-0.140
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.510
- DNA_REPAIR-0.490
- CHOLESTEROL_HOMEOSTASIS-0.430
- MYC_TARGETS_V1-0.430
- UV_RESPONSE_UP-0.430
- MYC_TARGETS_V2-0.420
- ALLOGRAFT_REJECTION-0.390
- FATTY_ACID_METABOLISM-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.977 |
| 2 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.962 |
| 3 | e356598b-7611-492a-98ed-ef2ec1b77b7a | — | — | 0.958 |
| 4 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.957 |
| 5 | SRR627429 | GTEX | — | 0.948 |
| 6 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.943 |
| 7 | d1447a31-64bb-4e70-ae50-eeff7a605f38 | — | — | 0.935 |
| 8 | TCGA-A7-A13G-01B-04R-A22O-07 | — | D | 0.930 |
| 9 | SRR627451 | GTEX | — | 0.927 |
| 10 | SRR627462 | GTEX | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.070 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |